PIMCO Corporate & Income Opportunity Fund, PIMCO Corporate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
46
PIMCO Corporate & Income Opportunity Fund, PIMCO Corporate & Income Strategy Fund, PIMCO Income Strategy Fund, PIMCO Income Strategy Fund II and PIMCO High Income Fund Announce Final Results of Tender Offers for Auction Rate Preferred Shares

NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- PIMCO Corporate & Income Opportunity Fund (NYSE: PTY), PIMCO Corporate & Income Strategy Fund (NYSE: PCN), PIMCO Income Strategy Fund (NYSE: PFL), PIMCO Income Strategy Fund II (NYSE: PFN) and PIMCO High Income Fund (NYSE: PHK) (each, a “Fund” and, together, the “Funds”) today announced the expiration and final results of each Fund’s previously announced voluntary tender offer (each, a “Tender Offer” and, together, the “Tender Offers”) for up to 100% of the Fund’s outstanding auction rate preferred shares (“ARPS”) at a price equal to 87%, with respect to PCN, PFL and PFN, 88%, with respect to PHK, and 93%, with respect to PTY, of the ARPS’ per share liquidation preference of $25,000 per share (or $21,750 per share for PCN, PFL and PFN, $22,000 per share for PHK and $23,250 per share for PTY) and any unpaid dividends accrued through the expiration date of the Tender Offers.  The Tender Offers expired on July 25, 2019, at 5:00 p.m. New York City time.  All ARPS that were validly tendered and not withdrawn during the offering period of the Tender Offers have been accepted for payment as set forth below.

PTY has accepted for payment 1,012 ARPS, which represents approximately 10.63% of its outstanding ARPS, and 8,506 ARPS will remain outstanding.

PCN has accepted for payment 1,280 ARPS, which represents approximately 57.63% of its outstanding ARPS, and 941 ARPS will remain outstanding.

PFL has accepted for payment 243 ARPS, which represents approximately 11.85% of its outstanding ARPS, and 1,808 ARPS will remain outstanding.

PFN will accept for payment 201 ARPS, which represents approximately 5.44% of its outstanding ARPS, and 3,497 ARPS will remain outstanding.

PHK will accept for payment 1,757 ARPS, which represents approximately 43.07% of its outstanding ARPS, and 2,322 ARPS will remain outstanding.

All ARPS that were not tendered will remain outstanding, and the terms of the outstanding ARPS will remain the same as prior to the Tender Offers.

Any questions regarding the Tender Offers can be directed to the Funds’ Tender Agent, Deutsche Bank Trust Company Americas, at (877) 843-9767.   Each Fund’s daily New York Stock Exchange closing market price for its common shares, net asset value per common share, as well as other information, including updated portfolio statistics and performance, are available at  www.pimco.com/closedendfunds .  The information on or accessible through www.pimco.com/closedendfunds is not incorporated by reference herein.

About PIMCO

PIMCO is one of the world’s premier fixed income investment managers.  With our launch in 1971 in Newport Beach, California, PIMCO introduced investors to a total return approach to fixed income investing.  In the 45+ years since, we have continued to bring innovation and expertise to our partnership with clients seeking the best investment solutions.  Today we have offices across the globe and 2,150+ professionals united by a single purpose: creating opportunities for investors in every environment.  PIMCO is owned by Allianz S.E., a leading global diversified financial services provider.

Except for the historical information and discussions contained herein, statements contained in this news release constitute forward-looking statements.  These statements may involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including the performance of financial markets, the investment performance of PIMCO's sponsored investment products and separately managed accounts, general economic conditions, future acquisitions, competitive conditions and government regulations, including changes in tax laws.  Readers should carefully consider such factors.  Further, such forward-looking statements speak only on the date at which such statements are made.  PIMCO undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product.  Neither the Funds, nor the Funds’ Boards of Trustees, nor PIMCO, makes any recommendation as to whether to tender or not to tender any ARPS in the Tender Offers.  No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission.  PIMCO is a trademark of Allianz Asset Management of America L.P. in the United States and throughout the world.  ©2019, PIMCO.

For information on the Tender Offers: Financial Advisors: (800) 628-1237 Shareholders: (844) 337-4626 or (844) 33-PIMCO PIMCO Media Relations: (212) 597-1054

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading